Carcinoembryonic antigen from human malignant melanoma cells. I. Production and shedding characteristics.
Two major findings are reported in the present studies: (a) Long-term cultivation, followed by cloning, of a human malignant melanoma HMMC-ShA cell line gave melanotic and amelanotic cell variants. During in vitro proliferation, the melanotic melanoma (HMMC-ShAE+) cells released carcinoembryonic antigen (CEA) and an inhibitor of phytohaemagglutinin-induced lymphocyte stimulation. Gel filtration patterns of CEA on Sephadex-G200 varied from one culture condition to another. Glycosylation-deficient CEA obtained from cells harvested from media supplemented with non-toxic levels of tunicamycin showed lower molecular weight and delayed filtration through Sephadex-G200. (b) Human melanotic melanoma (HMMC-ShAE+) differed from amelanotic melanoma (HMMC-ShA-) and glycosylation-deficient cells in the amount of CEA and in the suppression of lymphocyte response activity which they shed into the medium and as well as in oncogenicity in athymic nu/nu BALB/c mice.
D000818:Animals; D002272:Carcinoembryonic Antigen / Q000032:analysis* / Q000235:genetics / Q000276:immunology; D002460:Cell Line; D002471:Cell Transformation, Neoplastic / Q000276:immunology / Q000378:metabolism*; D002846:Chromatography, Affinity; D002850:Chromatography, Gel; D002999:Clone Cells / Q000276:immunology / Q000378:metabolism; D006801:Humans; D008213:Lymphocyte Activation; D008222:Lymphokines / Q000378:metabolism* / Q000502:physiology; D008543:Melanins / Q000096:biosynthesis; D008545:Melanoma / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D051379:Mice; D008819:Mice, Nude; D014415:Tunicamycin / Q000494:pharmacology
D002272:Carcinoembryonic Antigen; D008222:Lymphokines; D008543:Melanins; D014415:Tunicamycin